Wellington Management Group LLP Has $164.13 Million Stock Holdings in Kymera Therapeutics, Inc. $KYMR

Key Points

• Wellington Management Group LLP increased its stake in Kymera Therapeutics by 13.0% during the first quarter, owning approximately 9.21% of the company, valued at about $164 million.
• CEO Nello Mainolfi sold 30,000 shares for $1.47 million, reducing his ownership, while a director significantly increased their stake by purchasing 655,500 shares.
• Several analysts have given Kymera Therapeutics a "buy" rating, with a consensus target price of $59.11, highlighting positive market sentiment despite a recent earnings miss.

Wellington Management Group LLP raised its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 13.0% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,996,873 shares of the company's stock after purchasing an additional 689,547 shares during the period. Wellington Management Group LLP owned 9.21% of Kymera Therapeutics worth $164,134,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. KBC Group NV boosted its stake in Kymera Therapeutics by 15.2% during the 1st quarter. KBC Group NV now owns 2,479 shares of the company's stock valued at $68,000 after purchasing an additional 328 shares during the period. Summit Investment Advisors Inc. lifted its stake in shares of Kymera Therapeutics by 9.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after acquiring an additional 406 shares during the period. State of Wyoming acquired a new stake in shares of Kymera Therapeutics in the 4th quarter worth approximately $45,000. GF Fund Management CO. LTD. acquired a new stake in shares of Kymera Therapeutics in the 4th quarter worth approximately $55,000. Finally, GSA Capital Partners LLP lifted its stake in shares of Kymera Therapeutics by 6.8% in the 1st quarter. GSA Capital Partners LLP now owns 31,537 shares of the company's stock worth $863,000 after acquiring an additional 1,997 shares during the period.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bvf Partners L. P/Il bought 317,167 shares of the business's stock in a transaction that occurred on Monday, June 30th. The stock was acquired at an average cost of $44.00 per share, with a total value of $13,955,348.00. Following the completion of the purchase, the director directly owned 2,798,795 shares in the company, valued at approximately $123,146,980. This trade represents a 12.78% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Elena Ridloff sold 12,000 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $46.10, for a total transaction of $553,200.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 48,349 shares of company stock valued at $2,334,301. Corporate insiders own 16.01% of the company's stock.

Kymera Therapeutics Trading Up 4.9%

KYMR stock traded up $2.05 on Tuesday, hitting $43.87. 435,439 shares of the company's stock traded hands, compared to its average volume of 644,257. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $53.27. The stock has a market cap of $3.14 billion, a price-to-earnings ratio of -12.64 and a beta of 2.18. The stock has a fifty day moving average of $44.02 and a 200-day moving average of $36.67.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The business had revenue of $11.48 million for the quarter, compared to analyst estimates of $17.37 million. During the same period in the prior year, the company earned ($0.58) earnings per share. The firm's revenue for the quarter was down 55.1% on a year-over-year basis. On average, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

KYMR has been the subject of a number of research analyst reports. Oppenheimer reaffirmed an "outperform" rating and issued a $53.00 price target (down from $56.00) on shares of Kymera Therapeutics in a research note on Friday, June 27th. The Goldman Sachs Group raised shares of Kymera Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 15th. UBS Group reduced their price target on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Morgan Stanley initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $70.00 price target for the company. Finally, Wall Street Zen lowered shares of Kymera Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Kymera Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $58.76.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.